Medical device firm CryoCor has said that the US Patent and Trademark Office or USPTO has declared a patent interference between a patent application exclusively licensed by CryoCor and two patents held by CryoCath Technologies.
Subscribe to our email newsletter
The patent interference is related to certain pre-cooling technologies that CryoCor considers important to CryoCath’s cryoablation system. A patent interference is an administrative proceeding within the USPTO to establish which party was the first to invent certain subject matter and, therefore, should have patent rights to the technology.
Ed Brennan, president and CEO of CryoCor, said: “We believe we have broad coverage in our patent portfolio covering pre-cooling, which we consider important for a cryoablation system.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.